Rxim002

Phase 1

RRiboX Therapeutics Ltd.

Rxim002 is one of 4 therapeutic programs targeting Immune Thrombocytopenia (ITP). It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Immune Thrombocytopenia (ITP)Not yet recruiting

Immune Thrombocytopenia (ITP)Phase 1

Not yet recruiting

Competition

Competitive Landscape

4 competitors in Immune Thrombocytopenia (ITP)

#DrugCompanyPhaseTrials

Jaypirca

Eli Lilly

Preclinical

1 2

NVG-2089

NNuvig Therapeutics, Inc.

Phase 2

1 3

Vyvgart

Argenx

Preclinical

1 4

Rxim002

RRiboX Therapeutics Ltd.

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2029

Phase 1Not yet recruiting

Immune Thrombocytopenia (ITP)

NCT07765966

Clinical

Trials by Indication[1]

Immune Thrombocytopenia (ITP)1 trial

A Phase 1, Open Label, Dose Escalation Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Early Efficacy of RXIM002, in Patients With Relapsed or Refractory Autoimmune Cytopenias

Not yet recruiting·RRiboX Therapeutics Ltd.·Phase 1·NCT07765966·27 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Rxim002. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Rxim002. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — RiboX Therapeutics Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 1[1]
Company: RRiboX Therapeutics Ltd.

Rxim002

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q4 2029

Trials by Indication[1]

Immune Thrombocytopenia (ITP)1 trial

References

Drug Info

Quick Facts

Related News